Calliditas Therapeutics (CALT) reported data from the proof-of-concept Phase 2 trial evaluating setanaxib, the company's lead NOX ...
Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced data from the proof-of-concept Phase 2 ...
SCTIMST's 40th convocation awarded degrees to 162 graduands. Dr Saraswat commended their role as institute ambassadors, acknowledged NITI Aayog's coll ...